Boston Scientific has invested $1.5 billion to acquire about a 34% stake in MiRus, gaining exclusive rights to its investigational transcatheter aortic valve replacement (TAVR) system designed for severe aortic stenosis. The SIEGEL valve features a nickel-free, nitric oxide-coated rhenium alloy frame and smaller delivery profile, aiming for less invasive procedures. The device is still investigational and not yet approved for commercial use. Boston Scientific may pay up to $3 billion more if clinical and regulatory milestones are met, aligning with its strategy to expand its cardiovascular portfolio. MiRus has also launched the STAR pivotal trial to evaluate the valve's safety and effectiveness in over 1,000 patients across various risk groups.
